Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Colorectal Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 47 articles: HTML format Text format

Single Articles

January 2010
1. VAN IERSEL LB , Koopman M, van de Velde CJ, Mol L, et al
   Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy.
   Ann Oncol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
2. FOLEY KA , Wang PF, Barber BL, Long SR, et al
   Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab.
   Ann Oncol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. RINGLAND CL , Arkenau HT, O'Connell DL, Ward RL, et al
   Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry.
   Ann Oncol. 2010;21:92-7.
   PubMed     Text format     Related articles    Abstract available
   
   
   November 2009
4. SERUGA B , Hertz PC, Wang L, Booth CM, et al
   Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer.
   Ann Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. SHARMA S , Abhyankar V, Burgess RE, Infante J, et al
   A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
   Ann Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. TABERNERO J , Ciardiello F, Rivera F, Rodriguez-Braun E, et al
   Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
   Ann Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
7. WELCH S , Spithoff K, Rumble RB, Maroun J, et al
   Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review.
   Ann Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. GLIMELIUS B , Spindler KL, Frodin JE, Berglund A, et al
   Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study.
   Ann Oncol. 2009.
   PubMed     Text format     Related articles   
   
   
   
9. GLIMELIUS B , Lahn M, Gawande S, Cleverly A, et al
   A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer.
   Ann Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. SAAD ED , Katz A, Hoff PM, Buyse M, et al
    Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. RAMANATHAN RK , Rothenberg ML, de Gramont A, Tournigand C, et al
    Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
12. VAN STEENBERGEN LN , Rutten HJ, Creemers GJ, Pruijt JF, et al
    Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. STRIMPAKOS AS , Cunningham D, Mikropoulos C, Petkar I, et al
    The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. PARK JS , Kim HK, Choi YS, Kim K, et al
    Outcomes after repeated resection for recurrent pulmonary metastases from colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. TOL J , Koopman M, Miller MC, Tibbe A, et al
    Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. SPINDLER KL , Andersen RF, Jensen LH, Ploen J, et al
    EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. ZAANAN A , Cuilliere-Dartigues P, Guilloux A, Parc Y, et al
    Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. KOIZUMI W , Boku N, Yamaguchi K, Miyata Y, et al
    Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
19. KIM JG , Chae YS, Sohn SK, Moon JH, et al
    IVS10+12A>G polymorphism in hMSH2 gene associated with prognosis for patients with colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
20. ROSATI G , Cordio S, Bordonaro R, Caputo G, et al
    Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
21. MOL L , Koopman M, Ottevanger PB, Punt CJ, et al
    A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. QVORTRUP C , Jensen BV, Fokstuen T, Nielsen SE, et al
    A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. BUHMEIDA A , Bendardaf R, Hilska M, Laine J, et al
    PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma.
    Ann Oncol. 2009;20:1230-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
24. YCHOU M , Hohenberger W, Thezenas S, Navarro M, et al
    A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. ARSLAN C , Kilickap S
    FDG-PET: for early prediction of response to the first-line chemotherapy in metastatic colorectal cancer?
    Ann Oncol. 2009;20:1149-50.
    PubMed     Text format     Related articles   
    
    
    
26. NORDLINGER B , Van Cutsem E, Gruenberger T, Glimelius B, et al
    Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.
    Ann Oncol. 2009;20:985-92.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
27. CHIBAUDEL B , Tournigand C, Artru P, Andre T, et al
    FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. PIESSEVAUX H , Buyse M, De Roock W, Prenen H, et al
    Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. AFZAL S , Jensen SA, Vainer B, Vogel U, et al
    MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. CARLOMAGNO C , Farella A, Bucci L, D'Armiento FP, et al
    Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study.
    Ann Oncol. 2009;20:906-12.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. VAN CUTSEM E , Oliveira J
    Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    Ann Oncol. 2009;20 Suppl 4:61-3.
    PubMed     Text format     Related articles   
    
    
    
32. VASEN HF , van der Meulen-de Jong AE, de Vos Tot Nederveen Cappel WH, Oliveira J, et al
    Familial colorectal cancer risk: ESMO clinical recommendations.
    Ann Oncol. 2009;20 Suppl 4:51-3.
    PubMed     Text format     Related articles   
    
    
    
33. VAN CUTSEM E , Oliveira J
    Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
    Ann Oncol. 2009;20 Suppl 4:49-50.
    PubMed     Text format     Related articles   
    
    
    April 2009
34. VAN CUTSEM E , Rivera F, Berry S, Kretzschmar A, et al
    Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. NIELSEN DL , Pfeiffer P, Jensen BV
    Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab.
    Ann Oncol. 2009;20:798.
    PubMed     Text format     Related articles   
    
    
    March 2009
36. COHEN SJ , Punt CJ, Iannotti N, Saidman BH, et al
    Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. BENGALA C , Bettelli S, Bertolini F, Salvi S, et al
    Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.
    Ann Oncol. 2009;20:469-74.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
38. KEMENY N , Capanu M, D'Angelica M, Jarnagin W, et al
    Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
39. YCHOU M , Raoul JL, Douillard JY, Gourgou-Bourgade S, et al
    A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. GARM SPINDLER KL , Pallisgaard N, Rasmussen AA, Lindebjerg J, et al
    The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. BYSTROM P , Berglund A, Garske U, Jacobsson H, et al
    Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. DE VOGEL S , Weijenberg MP, Herman JG, Wouters KA, et al
    MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. ZANG DY , Lee BH, Park HC, Song HH, et al
    Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. BIDARD FC , Tournigand C, Andre T, Mabro M, et al
    Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. POSTMA C , Koopman M, Buffart TE, Eijk PP, et al
    DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
46. JURADO JM , Pajares B, Olmos D, Sevilla I, et al
    'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin.
    Ann Oncol. 2008;19:2093-4.
    PubMed     Text format     Related articles   
    
    
    
47. GOSENS MJ , Dresen RC, Rutten HJ, Nieuwenhuijzen GA, et al
    Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours.
    Ann Oncol. 2008;19:2026-32.
    PubMed     Text format     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: